Micafungin

From Wikipedia, the free encyclopedia

Micafungin
Systematic (IUPAC) name
Pneumocandin A0,1-[(4R,5R)-4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium
Identifiers
CAS number 235114-32-6
ATC code J02AX05
PubChem 477468
Chemical data
Formula C56H71N9O23S 
Mol. mass 1270.28 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

EU, US
Pregnancy cat.

C
Legal status

℞ Prescription only
Routes Intravenous

Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas.

Micafungin is administered intravenously. It has received final approval from the United States Food and Drug Administration on March 16, 2005.

Micafungin gained approval in the European Union on April 25, 2008.

Contents

[edit] Indications

Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, candida peritonitis, abscesses and esophageal candidiasis. On January 23, 2008, micafungin is now approved for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation.

[edit] Contraindications

Known hypersensitivity to micafungin or any other ingredient contained in the formulation.

[edit] Dosage

For the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses, the dosage of micafungin is 100 mg once daily. For the treatment of Esophageal Candidiasis, the dosage is 150 mg once daily. For the Prophylaxis of Candida Infections in HSCT Recipients, the dosage 50 mg once daily.

[edit] Dosage forms

  • Mycamine 50mg for i.v.-infusion (manufacturer Astellas)
  • Mycamine 100mg for i.v.-infusion (manufacturer Astellas)
  • Brand names in countries other than the US may vary.

[edit] External links

v • d • e
Antifungals (D01 and J02)
Antibiotics
Topical azoles
Other topicals
For systemic use
Other